Efficacy and safety of rituximab biosimilar (DRL_RI) versus MabThera in low-tumor-burden follicular lymphoma: the FLINTER study

Efficacy and safety of rituximab biosimilar (DRL_RI) versus MabThera in low-tumor-burden follicular lymphoma: the FLINTER study

Background and objectives: This phase III study (RI-01-006; FLINTER) was conducted to demonstrate equivalent efficacy of DRL_RI to EU-approved rituximab (MabThera ® ) in patients with previously untreated Stage II–IV, CD20-positive, low-tumor-burden follicular lymphoma (LTB-FL). This study also eval...

Full description

Saved in:
Bibliographic Details
Main Authors: Narendra Maharaj, Dharma Rao Uppada, Anand Eswaraiah, Ranjith Kakkattu, Pramod Reddy, Volha A. Kalenik, David Belada, Ana Oliveira Ramos, Jin Seok Kim, Yauheni V. Baranau
Format: Article
Language:English
Published: SAGE Publishing 2025-05-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359251339925
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items